/
ENLV
$0.58+$0.01 (+1.75%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$137.4M
241M shares
52-week range
$0.56 – $2.10
2% from low
Exchange
NASDAQ
CS
Borrow rate
217.22%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-8.32
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.3M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $121.0K | $297.0K | $286.0K | $546.0K | $777.0K | $835.0K | $545.0K | $332.0K |
| Gross profit | −$121.0K | −$297.0K | −$286.0K | −$546.0K | −$777.0K | −$835.0K | −$545.0K | −$332.0K |
| Gross margin | — | — | -12.6% | — | — | — | — | — |
| R&D | $4.3M | $5.7M | $6.1M | $12.9M | $18.7M | $19.2M | $10.1M | $8.9M |
| Operating income | −$5.3M | −$8.6M | −$9.8M | −$19.3M | −$25.8M | −$29.4M | −$15.5M | −$15.0M |
| EBITDA | −$5.2M | −$9.1M | −$9.5M | −$18.7M | −$25.0M | −$28.2M | −$14.5M | −$14.7M |
| Net income | −$4.9M | −$9.4M | −$11.8M | −$14.5M | −$31.1M | −$29.1M | −$15.0M | $1.24B |
| Net margin | — | — | -519.3% | — | — | — | — | — |
| EPS (diluted) | -10.63 | -1.17 | -1.05 | -0.54 | -2.31 | -1.56 | -0.73 | 25.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.08 | $-0.08–$-0.08 | 1 |
| 2027 | $0 | $-0.09 | $-0.09–$-0.09 | 1 |
| 2028 | $0 | $-0.94 | $-0.94–$-0.94 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Enlivex Ltd. Ordinary Shares
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
www.enlivex.com- Employees
- 34
- IPO / List date
- Jul 31, 2014
Held by traders on TradeandTell
No one on the platform currently holds ENLV.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ENLV as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-03-06 | 1-for-8reverse |
| 2017-09-25 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded ENLV yet.
